Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
Keywan Mortezaee, Jamal Majidpoor, Sajad Najafi, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 158, pp. 114150-114150
Open Access | Times Cited: 19

Showing 19 citing articles:

Advances in dendritic cell vaccination therapy of cancer
Sajad Najafi, Keywan Mortezaee
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114954-114954
Open Access | Times Cited: 49
The role of microRNAs in the pathophysiology of human central nervous system: A focus on neurodegenerative diseases
Delsuz Rezaee, Fatemeh Saadatpour, Nayyereh Akbari, et al.
Ageing Research Reviews (2023) Vol. 92, pp. 102090-102090
Closed Access | Times Cited: 38
Extracellular vesicle–based drug delivery in cancer immunotherapy
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Drug Delivery and Translational Research (2023) Vol. 13, Iss. 11, pp. 2790-2806
Open Access | Times Cited: 37
The role of microRNA-185 in the pathogenesis of human diseases: A focus on cancer
Safoora Pordel, Motahare Khorrami, Fatemeh Saadatpour, et al.
Pathology - Research and Practice (2023) Vol. 249, pp. 154729-154729
Open Access | Times Cited: 30
Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
Keywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114824-114824
Open Access | Times Cited: 24
microRNA-184 in the landscape of human malignancies: a review to roles and clinical significance
Mehdi Fattahi, Delsuz Rezaee, Fatemeh Fakhari, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 22
WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
Keywan Mortezaee
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 14
The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations
Angela Santoro, Giuseppe Angelico, Frediano Inzani, et al.
Gynecologic Oncology (2024) Vol. 184, pp. 57-66
Open Access | Times Cited: 13
Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated
Arian Charehjoo, Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology (2023) Vol. 118, pp. 110032-110032
Closed Access | Times Cited: 16
Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies
Sajad Najafi, Keywan Mortezaee
Life Sciences (2023) Vol. 338, pp. 122387-122387
Closed Access | Times Cited: 14
Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer
Shaukat Ali, Mahnoor Arshad, Muhammad Summer, et al.
Journal of Oncology Pharmacy Practice (2025)
Closed Access
Tumor-educated platelets
Sajad Najafi, Yahya Asemani, Jamal Majidpoor, et al.
Clinica Chimica Acta (2023) Vol. 552, pp. 117690-117690
Closed Access | Times Cited: 12
B7x in cancer immunity and immunotherapy
Keywan Mortezaee
International Immunopharmacology (2023) Vol. 118, pp. 110133-110133
Closed Access | Times Cited: 10
Liquid biopsy in colorectal cancer
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Clinica Chimica Acta (2023) Vol. 553, pp. 117674-117674
Closed Access | Times Cited: 8
Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses
Keywan Mortezaee, Jamal Majidpoor
Heliyon (2023) Vol. 9, Iss. 3, pp. e14566-e14566
Open Access | Times Cited: 7
Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management
Rosanna Ruggiero, Raffaella Di Napoli, Nunzia Balzano, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 5, pp. 423-434
Closed Access | Times Cited: 7
Circulating circRNA: a social butterfly in tumors
Shuo Miao, Qingsong Zhang
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114436-114436
Open Access | Times Cited: 4
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report
Carolin Krekeler, Klaus Wethmar, Jan‐Henrik Mikesch, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12056-12056
Open Access | Times Cited: 4
Page 1

Scroll to top